Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine

Leukemia

Volumn 24, Issue 1, 2010, Pages 236-237

  Wermke, M ^a   Thiede, C ^a   Kiani, A ^a   Ehninger, G ^a   Bornhauser M ^a   Platzbecker, U ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; NUCLEOPHOSMIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CASE REPORT; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUTROPENIA; PRIORITY JOURNAL;

EID: 74249118052     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.204     Document Type: Letter

References (8)

1. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011-4020.
2. Papadaki C, Dufour A, Seibl M, Schneider S, Bohlander SK, Zellmeier E et al. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 2009; 144: 517-523.
3. Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y et al. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. Exp Hematol 2009; 37: 659-672.
4. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007; 25: 3884-3891.
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
6. O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377-386.
7. Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2009 (Epub ahead of print).
8. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cyto-genetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918.